Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Author(s):
Meyer, S.; Nederend, M.; Jansen, J.H.M.; Reiding, K.R.; Jacobino, S.R.; Meeldijk, J.; Bovenschen, N.; Wuhrer, M. (0000-0002-0814-4995); Valerius, T.; Ubink, R.; Boross, P.; Rouwendal, G.; Leusen, J.H.W.
Published
2016
Publication type
Article / Letter to editor
albumin-binding domain (ABD)antibody therapyFc a receptor (FcaRI)glycosylationhalf-life extensionIgAneonatal Fc receptor (FcRn)serum exposure
Date issued
2016-01-02
Language
English
Is part of
mAbs (2016), Vol. 8, no. 1, p. 87-98
hdl
1887/101820
doi
10.1080/19420862.2015.1106658